FDA Approves Sacituzumab Govitecan for Pretreated HR+/HER2-Metastatic Breast Cancer

被引：0
作者：
不详
机构：
来源：
AMERICAN JOURNAL OF MANAGED CARE | 2023年 / 29卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：SP315 / SP315
页数：1
相关论文
共 3 条
  • [1] [Anonymous], 2023, News release
  • [2] FDA, 2021, FDA GRANTS REG APPR
  • [3] Overall survival (OS) results from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with HR+/HER2-metastatic breast cancer (mBC)
    Rugo, H. S.
    Bardia, A.
    Marme, F.
    Cortes, J.
    Schmid, P.
    Loirat, D.
    Tredan, O.
    Ciruelos, E. M.
    Dalenc, F.
    Gomez Pardo, P.
    Jhaveri, K.
    Delaney, R. J.
    Valdez, T.
    Wang, H.
    Verret, W.
    Tolaney, S. M.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1386 - S1386
1